WuXi Biologics and ABL Bio Corporation announced that the companies have entered into an exclusive development and clinical manufacturing partnership for up to 8 antibody therapeutics including ABL Bio's biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab). The agreement showcases the expansive biologics pipeline of ABL Bio and the world leading technical expertise and capabilities of WuXi Biologics in developing bispecific programs.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25,400 KRW | -0.59% | +7.86% | +3.25% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.25% | 900M | |
+8.36% | 115B | |
+13.01% | 107B | |
-13.59% | 22.31B | |
-3.99% | 21.6B | |
-5.62% | 18.23B | |
-39.93% | 17.62B | |
+7.67% | 14.26B | |
+33.33% | 12.37B | |
-28.05% | 8.28B |
- Stock Market
- Equities
- A298380 Stock
- News ABL Bio Inc.
- WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies